[{"indications": "Indications\u00a0see under preparations, below", "name": "EPOETIN ALFA, BETA, THETA, and ZETA", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "9 Nutrition and blood", "9.1 Anaemias and some other blood disorders", "9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias", "Erythropoietins", "EPOETIN ALFA, BETA, THETA, and ZETA"], "cautions": "Cautions\u00a0\n(From Erythropoietins: British National Formulary)\nErythropoietins; also inadequately treated or poorly controlled blood pressure (monitor closely blood pressure,\r\nreticulocyte counts, haemoglobin, and electrolytes), interrupt treatment if blood pressure uncontrolled; sudden stabbing migraine-like pain\r\nis warning of a hypertensive crisis; sickle-cell\r\ndisease (lower target haemoglobin concentration may be appropriate); ischaemic vascular disease; thrombocytosis (monitor platelet count for first 8 weeks); epilepsy; malignant disease; increase in unfractionated or low molecular weight heparin dose may be needed during dialysis; risk of thrombosis may be increased when used for\r\nanaemia in adults receiving cancer chemotherapy; risk of thrombosis may be increased when used for anaemia before\r\northopaedic surgery\u2014avoid in cardiovascular disease\r\nincluding recent myocardial infarction or cerebrovascular accident", "side-effects": "Side-effects\u00a0diarrhoea, nausea, vomiting; dose-dependent increase\r\nin blood pressure or aggravation of hypertension; in isolated patients\r\nwith normal or low blood pressure, hypertensive crisis with encephalopathy-like\r\nsymptoms and generalised tonic-clonic seizures requiring immediate\r\nmedical attention; headache; dose-dependent increase in platelet count\r\n(but thrombocytosis rare) regressing during treatment; influenza-like\r\nsymptoms (may be reduced if intravenous injection given over 5 minutes);\r\ncardiovascular events; shunt thrombosis especially if tendency to\r\nhypotension or arteriovenous shunt complications; very rarely sudden loss of efficacy because of pure red cell aplasia, particularly\r\nfollowing subcutaneous administration in patients with chronic renal\r\nfailure (discontinue erythropoietin therapy)\u2014see also notes above, hyperkalaemia,\r\nhypersensitivity reactions (including anaphylaxis and angioedema),\r\nskin reactions, injection-site reactions, and peripheral oedema also\r\nreported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/201277.htm", "doses": ["See under preparations, below"], "pregnancy": "Pregnancy\u00a0no evidence of harm; benefits probably outweigh risk\r\nof anaemia and of transfusion in pregnancy"}, {"indications": "Indications\u00a0see under preparations, below", "name": "EPOETIN ALFA, BETA, THETA, and ZETA Epoetin alfa", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "9 Nutrition and blood", "9.1 Anaemias and some other blood disorders", "9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias", "Erythropoietins", "EPOETIN ALFA, BETA, THETA, and ZETA", "Epoetin alfa"], "cautions": "Cautions\u00a0\n(From Erythropoietins: British National Formulary)\nErythropoietins; also inadequately treated or poorly controlled blood pressure (monitor closely blood pressure,\r\nreticulocyte counts, haemoglobin, and electrolytes), interrupt treatment if blood pressure uncontrolled; sudden stabbing migraine-like pain\r\nis warning of a hypertensive crisis; sickle-cell\r\ndisease (lower target haemoglobin concentration may be appropriate); ischaemic vascular disease; thrombocytosis (monitor platelet count for first 8 weeks); epilepsy; malignant disease; increase in unfractionated or low molecular weight heparin dose may be needed during dialysis; risk of thrombosis may be increased when used for\r\nanaemia in adults receiving cancer chemotherapy; risk of thrombosis may be increased when used for anaemia before\r\northopaedic surgery\u2014avoid in cardiovascular disease\r\nincluding recent myocardial infarction or cerebrovascular accident", "side-effects": "Side-effects\u00a0diarrhoea, nausea, vomiting; dose-dependent increase\r\nin blood pressure or aggravation of hypertension; in isolated patients\r\nwith normal or low blood pressure, hypertensive crisis with encephalopathy-like\r\nsymptoms and generalised tonic-clonic seizures requiring immediate\r\nmedical attention; headache; dose-dependent increase in platelet count\r\n(but thrombocytosis rare) regressing during treatment; influenza-like\r\nsymptoms (may be reduced if intravenous injection given over 5 minutes);\r\ncardiovascular events; shunt thrombosis especially if tendency to\r\nhypotension or arteriovenous shunt complications; very rarely sudden loss of efficacy because of pure red cell aplasia, particularly\r\nfollowing subcutaneous administration in patients with chronic renal\r\nfailure (discontinue erythropoietin therapy)\u2014see also notes above, hyperkalaemia,\r\nhypersensitivity reactions (including anaphylaxis and angioedema),\r\nskin reactions, injection-site reactions, and peripheral oedema also\r\nreported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/200804.htm", "doses": ["See under preparations, below", "Name[Binocrit\u00ae (Sandoz)  ] Injection, prefilled syringe, epoetin\r\nalfa, net price 1000\u00a0units = \u00a35.09; 2000\u00a0units = \u00a310.18; 3000\u00a0units\r\n= \u00a315.27; 4000\u00a0units = \u00a320.36; 5000\u00a0units = \u00a325.46; 6000\u00a0units = \u00a330.55;\r\n8000\u00a0units = \u00a340.73; 10\u00a0000\u00a0units = \u00a350.91Note\u00a0Biosimilar medicineDose\u00a0symptomatic anaemia associated with chronic renal failure\r\nin patients on haemodialysis (see also MHRA/CHM advice), by intravenous injection over 1\u20135 minutes, initially 50\u00a0units/kg\r\n3 times weekly adjusted according to response in steps of 25\u00a0units/kg\r\n3 times weekly at intervals of at least 4 weeks; maintenance dose,\r\nusually 25\u2013100\u00a0units/kg 3 times weekly; child by intravenous injection initially as for adults;\r\nmaintenance dose, body-weight under 10\u00a0kg usually 75\u2013150\u00a0units/kg\r\n3 times weekly, body-weight 10\u201330\u00a0kg usually 60\u2013150\u00a0units/kg 3 times\r\nweekly, body-weight over 30\u00a0kg usually 30\u2013100\u00a0units/kg 3 times weeklySymptomatic anaemia associated with chronic renal failure\r\nin adults on peritoneal dialysis (see also MHRA/CHM advice), by intravenous injection over 1\u20135 minutes, initially 50\u00a0units/kg\r\ntwice weekly; maintenance dose 25\u201350\u00a0units/kg twice weeklySevere symptomatic anaemia of renal origin in adults with\r\nrenal insufficiency not yet on dialysis (see also MHRA/CHM advice), by intravenous injection over 1\u20135 minutes, initially 50\u00a0units/kg\r\n3 times weekly increased according to response in steps of 25\u00a0units/kg\r\n3 times weekly at intervals of at least 4 weeks; maintenance dose\r\n17\u201333\u00a0units/kg 3 times weekly; max. 200\u00a0units/kg 3 times weeklyNote\u00a0Reduce dose by approximately 25% if rise\r\nin haemoglobin concentration exceeds 2\u00a0g/100\u00a0mL over 4 weeks or if\r\nhaemoglobin concentration exceeds 12\u00a0g/100\u00a0mL; if haemoglobin concentration\r\ncontinues to rise, despite dose reduction, suspend treatment until\r\nhaemoglobin concentration decreases and then restart at a dose approximately\r\n25% lower than the previous dose.Symptomatic anaemia in adults receiving cancer chemotherapy\r\n(see also MHRA/CHM advice), by subcutaneous injection (max. 1\u00a0mL per injection site),\r\ninitially 150\u00a0units/kg 3 times weekly (or 450\u00a0units/kg\r\nonce weekly), increased if appropriate rise in haemoglobin (or reticulocyte\r\ncount) not achieved after 4 weeks to 300\u00a0units/kg 3 times weekly;\r\ndiscontinue if inadequate response after 4 weeks at higher doseNote\u00a0Reduce dose by approximately 25\u201350% if rise\r\nin haemoglobin concentration exceeds 2\u00a0g/100\u00a0mL over 4 weeks or if\r\nhaemoglobin concentration exceeds 12\u00a0g/100\u00a0mL; if haemoglobin concentration\r\ncontinues to rise, despite dose reduction, suspend treatment until\r\nhaemoglobin concentration decreases and then restart at a dose approximately\r\n25% lower than the previous dose. Discontinue approximately 4 weeks\r\nafter ending chemotherapyTo increase yield of autologous blood (to avoid homologous\r\nblood) in predonation programme in moderate anaemia either when large volume of blood required or when sufficient\r\nblood cannot be saved for elective major surgery, by intravenous\r\ninjection over 1\u20135 minutes, 600\u00a0units/kg twice weekly for\r\n3 weeks before surgery; consult product literature for details and\r\nadvice on ensuring high iron storesModerate anaemia (haemoglobin concentration 10\u201313\u00a0g/100\u00a0mL)\r\nbefore elective orthopaedic surgery in adults with expected moderate\r\nblood loss to reduce exposure to allogeneic blood transfusion or if\r\nautologous transfusion unavailable, by subcutaneous injection (max. 1\u00a0mL per injection site), 600\u00a0units/kg every week for 3 weeks\r\nbefore surgery and on day of surgery or 300\u00a0units/kg\r\ndaily for 15 days starting 10 days before surgery; consult product\r\nliterature for details"], "pregnancy": "Pregnancy\u00a0no evidence of harm; benefits probably outweigh risk\r\nof anaemia and of transfusion in pregnancy"}, {"indications": "Indications\u00a0see under preparations, below", "name": "EPOETIN ALFA, BETA, THETA, and ZETA Epoetin theta", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "9 Nutrition and blood", "9.1 Anaemias and some other blood disorders", "9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias", "Erythropoietins", "EPOETIN ALFA, BETA, THETA, and ZETA", "Epoetin theta"], "cautions": "Cautions\u00a0\n(From Erythropoietins: British National Formulary)\nErythropoietins; also inadequately treated or poorly controlled blood pressure (monitor closely blood pressure,\r\nreticulocyte counts, haemoglobin, and electrolytes), interrupt treatment if blood pressure uncontrolled; sudden stabbing migraine-like pain\r\nis warning of a hypertensive crisis; sickle-cell\r\ndisease (lower target haemoglobin concentration may be appropriate); ischaemic vascular disease; thrombocytosis (monitor platelet count for first 8 weeks); epilepsy; malignant disease; increase in unfractionated or low molecular weight heparin dose may be needed during dialysis; risk of thrombosis may be increased when used for\r\nanaemia in adults receiving cancer chemotherapy; risk of thrombosis may be increased when used for anaemia before\r\northopaedic surgery\u2014avoid in cardiovascular disease\r\nincluding recent myocardial infarction or cerebrovascular accident", "side-effects": "Side-effects\u00a0diarrhoea, nausea, vomiting; dose-dependent increase\r\nin blood pressure or aggravation of hypertension; in isolated patients\r\nwith normal or low blood pressure, hypertensive crisis with encephalopathy-like\r\nsymptoms and generalised tonic-clonic seizures requiring immediate\r\nmedical attention; headache; dose-dependent increase in platelet count\r\n(but thrombocytosis rare) regressing during treatment; influenza-like\r\nsymptoms (may be reduced if intravenous injection given over 5 minutes);\r\ncardiovascular events; shunt thrombosis especially if tendency to\r\nhypotension or arteriovenous shunt complications; very rarely sudden loss of efficacy because of pure red cell aplasia, particularly\r\nfollowing subcutaneous administration in patients with chronic renal\r\nfailure (discontinue erythropoietin therapy)\u2014see also notes above, hyperkalaemia,\r\nhypersensitivity reactions (including anaphylaxis and angioedema),\r\nskin reactions, injection-site reactions, and peripheral oedema also\r\nreported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/208136.htm", "doses": ["See under preparations, below", "By intravenous injection, adult over 18 years, initially 40\u00a0units/kg 3 times weekly, increased according\r\nto response to 80\u00a0units/kg 3 times weekly after 4 weeks, with further\r\nincreases if needed at intervals of 4 weeks in steps of 25% of the\r\nprevious dose; maintenance dose, adjusted if necessary in steps of\r\n25%; weekly maintenance dose may be given in 2 divided doses in stable\r\npatients; max. 700\u00a0units/kg weekly", "Name[Eporatio\u00ae (Ratiopharm UK)  ] Injection, prefilled syringe, epoetin\r\ntheta, net price 1000\u00a0units = \u00a35.99; 2000\u00a0units = \u00a311.98; 3000\u00a0units\r\n= \u00a317.98; 4000\u00a0units = \u00a323.97; 5000\u00a0units = \u00a329.96; 10 000\u00a0units =\r\n\u00a359.92; 20 000\u00a0units = \u00a3119.84; 30 000\u00a0units = \u00a3179.75Note \u00a0If epoetin theta is substituted for another\r\nepoetin the same route of administration should be usedDose\u00a0symptomatic anaemia associated with chronic renal failure\r\n(see also MHRA/CHM advice), by subcutaneous injection, adult over 18 years, initially 20\u00a0units/kg 3 times weekly, increased after\r\n4 weeks according to response to 40\u00a0units/kg 3 times weekly, with\r\nfurther increases if needed at 4-weekly intervals in steps of 25%\r\nof the previous dose; maintenance dose, adjusted if necessary in steps\r\nof 25%; weekly maintenance dose may be given as a single dose or in\r\n3 divided doses; max. 700\u00a0units/kg weeklyBy intravenous injection, adult over 18 years, initially 40\u00a0units/kg 3 times weekly, increased according\r\nto response to 80\u00a0units/kg 3 times weekly after 4 weeks, with further\r\nincreases if needed at intervals of 4 weeks in steps of 25% of the\r\nprevious dose; maintenance dose, adjusted if necessary in steps of\r\n25%; weekly maintenance dose may be given in 2 divided doses in stable\r\npatients; max. 700\u00a0units/kg weeklyNote\u00a0Subcutaneous route preferred in patients\r\nnot on haemodialysis. Reduce dose by 25\u201350% if rise in haemoglobin\r\nconcentration exceeds 2\u00a0g/100\u00a0mL over 4 weeks or if haemoglobin concentration\r\napproaches or exceeds 12\u00a0g/100\u00a0mL; if haemoglobin concentration continues\r\nto rise, despite dose reduction, suspend treatment until haemoglobin\r\nconcentration decreases and then restart at a dose approximately 25%\r\nlower than the previous doseSymptomatic anaemia in adults with non-myeloid malignancies\r\nreceiving cancer chemotherapy (see also MHRA/CHM advice), by subcutaneous injection, initially 20\u00a0000\u00a0units once weekly,\r\nincreased if necessary after 4 weeks (if a rise in haemoglobin of\r\nat least 1\u00a0g/100\u00a0mL not achieved) to 40\u00a0000\u00a0units once weekly, with\r\nfurther increase if needed after 4 weeks to max. 60\u00a0000\u00a0units once\r\nweeklyNote\u00a0Discontinue treatment if haemoglobin concentration\r\ndoes not increase by at least 1\u00a0g/100\u00a0mL after 12 weeks of therapy\r\n(response unlikely). Reduce dose by 25\u201350% if rise in haemoglobin\r\nconcentration exceeds 2\u00a0g/100\u00a0mL over 4 weeks or if haemoglobin concentration\r\nexceeds 12\u00a0g/100\u00a0mL; if haemoglobin concentration continues to rise,\r\ndespite dose reduction, suspend treatment until haemoglobin concentration\r\ndecreases and then restart at a dose approximately 25% lower than\r\nthe previous dose. Discontinue approximately 4 weeks after ending\r\nchemotherapy"], "pregnancy": "Pregnancy\u00a0no evidence of harm; benefits probably outweigh risk\r\nof anaemia and of transfusion in pregnancy"}, {"indications": "Indications\u00a0see under preparations, below", "name": "EPOETIN ALFA, BETA, THETA, and ZETA Epoetin zeta", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "9 Nutrition and blood", "9.1 Anaemias and some other blood disorders", "9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias", "Erythropoietins", "EPOETIN ALFA, BETA, THETA, and ZETA", "Epoetin zeta"], "cautions": "Cautions\u00a0\n(From Erythropoietins: British National Formulary)\nErythropoietins; also inadequately treated or poorly controlled blood pressure (monitor closely blood pressure,\r\nreticulocyte counts, haemoglobin, and electrolytes), interrupt treatment if blood pressure uncontrolled; sudden stabbing migraine-like pain\r\nis warning of a hypertensive crisis; sickle-cell\r\ndisease (lower target haemoglobin concentration may be appropriate); ischaemic vascular disease; thrombocytosis (monitor platelet count for first 8 weeks); epilepsy; malignant disease; increase in unfractionated or low molecular weight heparin dose may be needed during dialysis; risk of thrombosis may be increased when used for\r\nanaemia in adults receiving cancer chemotherapy; risk of thrombosis may be increased when used for anaemia before\r\northopaedic surgery\u2014avoid in cardiovascular disease\r\nincluding recent myocardial infarction or cerebrovascular accident", "side-effects": "Side-effects\u00a0diarrhoea, nausea, vomiting; dose-dependent increase\r\nin blood pressure or aggravation of hypertension; in isolated patients\r\nwith normal or low blood pressure, hypertensive crisis with encephalopathy-like\r\nsymptoms and generalised tonic-clonic seizures requiring immediate\r\nmedical attention; headache; dose-dependent increase in platelet count\r\n(but thrombocytosis rare) regressing during treatment; influenza-like\r\nsymptoms (may be reduced if intravenous injection given over 5 minutes);\r\ncardiovascular events; shunt thrombosis especially if tendency to\r\nhypotension or arteriovenous shunt complications; very rarely sudden loss of efficacy because of pure red cell aplasia, particularly\r\nfollowing subcutaneous administration in patients with chronic renal\r\nfailure (discontinue erythropoietin therapy)\u2014see also notes above, hyperkalaemia,\r\nhypersensitivity reactions (including anaphylaxis and angioedema),\r\nskin reactions, injection-site reactions, and peripheral oedema also\r\nreported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/201278.htm", "doses": ["See under preparations, below", "Name[Retacrit\u00ae (Hospira)  ] Injection, prefilled syringe, epoetin\r\nzeta, net price 1000\u00a0units = \u00a35.66; 2000\u00a0units = \u00a311.31; 3000\u00a0units\r\n= \u00a316.97; 4000\u00a0units = \u00a322.63; 5000\u00a0units = \u00a328.28; 6000\u00a0units = \u00a333.94;\r\n8000\u00a0units = \u00a345.25; 10\u00a0000\u00a0units = \u00a356.57; 20\u00a0000\u00a0units = \u00a3113.13;\r\n30 000\u00a0units = \u00a3169.70; 40\u00a0000\u00a0units = \u00a3226.26Excipients  include phenylalanine up to 500\u00a0micrograms/syringe (section 9.4.1)Note\u00a0Biosimilar medicineDose\u00a0symptomatic anaemia associated with chronic renal failure\r\nin patients on haemodialysis (see also MHRA/CHM advice), by intravenous injection over 1\u20135 minutes or by subcutaneous injection (max. 1\u00a0mL per injection\r\nsite), initially 50\u00a0units/kg 3 times weekly adjusted according to\r\nresponse in steps of 25\u00a0units/kg 3 times weekly at intervals of at\r\nleast 4 weeks; maintenance dose, usually 25\u2013100\u00a0units/kg 3 times weekly; child by intravenous injection initially\r\nas for adults; maintenance dose, body-weight under 10\u00a0kg usually 75\u2013150\u00a0units/kg\r\n3 times weekly, body-weight 10\u201330\u00a0kg usually 60\u2013150\u00a0units/kg 3 times\r\nweekly, body-weight over 30\u00a0kg usually 30\u2013100\u00a0units/kg 3 times weeklySymptomatic anaemia associated with chronic renal failure\r\nin adults on peritoneal dialysis (see also MHRA/CHM advice), by intravenous injection over 1\u20135 minutes or by subcutaneous injection (max. 1\u00a0mL per injection\r\nsite), initially 50\u00a0units/kg twice weekly; maintenance dose 25\u201350\u00a0units/kg\r\ntwice weeklySevere symptomatic anaemia of renal origin in adults with\r\nrenal insufficiency not yet on dialysis (see also MHRA/CHM advice), by intravenous injection over 1\u20135 minutes or by subcutaneous injection (max. 1\u00a0mL per injection\r\nsite), initially 50\u00a0units/kg 3 times weekly increased according to\r\nresponse in steps of 25\u00a0units/kg 3 times weekly at intervals of at\r\nleast 4 weeks; maintenance dose 17\u201333\u00a0units/kg 3 times weekly; max.\r\n200\u00a0units/kg 3 times weeklyNote\u00a0Avoid increasing haemoglobin concentration\r\nat a rate exceeding 2\u00a0g/100\u00a0mL over 4 weeksSymptomatic anaemia in adults receiving cancer chemotherapy\r\n(see also MHRA/CHM advice), by subcutaneous injection (max. 1\u00a0mL per injection site),\r\ninitially 150\u00a0units/kg 3 times weekly (or 450\u00a0units/kg\r\nonce weekly), increased if appropriate rise in haemoglobin (or reticulocyte\r\ncount) not achieved after 4 weeks to 300\u00a0units/kg 3 times weekly;\r\ndiscontinue if inadequate response after 4 weeks at higher doseNote\u00a0Reduce dose by approximately 25\u201350% if rise\r\nin haemoglobin concentration exceeds 2\u00a0g/100\u00a0mL over 4 weeks or if\r\nhaemoglobin concentration exceeds 12\u00a0g/100\u00a0mL; if haemoglobin concentration\r\ncontinues to rise, despite dose reduction, suspend treatment until\r\nhaemoglobin concentration decreases and then restart at a dose approximately\r\n25% lower than the previous dose. Discontinue approximately 4 weeks\r\nafter ending chemotherapyTo increase yield of autologous blood (to avoid homologous blood)\r\nin predonation programme in moderate anaemia either when large volume of blood required or when sufficient\r\nblood cannot be saved for elective major surgery, by intravenous\r\ninjection over 1\u20135 minutes, 600\u00a0units/kg twice weekly for\r\n3 weeks before surgery; consult product literature for details and\r\nadvice on ensuring high iron storesModerate anaemia (haemoglobin concentration 10\u201313\u00a0g/100\u00a0mL)\r\nbefore elective orthopaedic surgery in adults with expected moderate\r\nblood loss to reduce exposure to allogeneic blood transfusion or if\r\nautologous transfusion unavailable, by subcutaneous injection (max. 1\u00a0mL per injection site), 600\u00a0units/kg every week for 3 weeks\r\nbefore surgery and on day of surgery or 300\u00a0units/kg\r\ndaily for 15 days starting 10 days before surgery; consult product\r\nliterature for details"], "pregnancy": "Pregnancy\u00a0no evidence of harm; benefits probably outweigh risk\r\nof anaemia and of transfusion in pregnancy"}, {"indications": "Indications\u00a0see under preparations, below", "name": "EPOETIN ALFA, BETA, THETA, and ZETA Epoetin beta", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "9 Nutrition and blood", "9.1 Anaemias and some other blood disorders", "9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias", "Erythropoietins", "EPOETIN ALFA, BETA, THETA, and ZETA", "Epoetin beta"], "cautions": "Cautions\u00a0\n(From Erythropoietins: British National Formulary)\nErythropoietins; also inadequately treated or poorly controlled blood pressure (monitor closely blood pressure,\r\nreticulocyte counts, haemoglobin, and electrolytes), interrupt treatment if blood pressure uncontrolled; sudden stabbing migraine-like pain\r\nis warning of a hypertensive crisis; sickle-cell\r\ndisease (lower target haemoglobin concentration may be appropriate); ischaemic vascular disease; thrombocytosis (monitor platelet count for first 8 weeks); epilepsy; malignant disease; increase in unfractionated or low molecular weight heparin dose may be needed during dialysis; risk of thrombosis may be increased when used for\r\nanaemia in adults receiving cancer chemotherapy; risk of thrombosis may be increased when used for anaemia before\r\northopaedic surgery\u2014avoid in cardiovascular disease\r\nincluding recent myocardial infarction or cerebrovascular accident", "side-effects": "Side-effects\u00a0diarrhoea, nausea, vomiting; dose-dependent increase\r\nin blood pressure or aggravation of hypertension; in isolated patients\r\nwith normal or low blood pressure, hypertensive crisis with encephalopathy-like\r\nsymptoms and generalised tonic-clonic seizures requiring immediate\r\nmedical attention; headache; dose-dependent increase in platelet count\r\n(but thrombocytosis rare) regressing during treatment; influenza-like\r\nsymptoms (may be reduced if intravenous injection given over 5 minutes);\r\ncardiovascular events; shunt thrombosis especially if tendency to\r\nhypotension or arteriovenous shunt complications; very rarely sudden loss of efficacy because of pure red cell aplasia, particularly\r\nfollowing subcutaneous administration in patients with chronic renal\r\nfailure (discontinue erythropoietin therapy)\u2014see also notes above, hyperkalaemia,\r\nhypersensitivity reactions (including anaphylaxis and angioedema),\r\nskin reactions, injection-site reactions, and peripheral oedema also\r\nreported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/65387.htm", "doses": ["See under preparations, below", "symptomatic anaemia associated with chronic renal failure\r\n(see also MHRA/CHM advice), by subcutaneous injection, adult and child over 3 years, initially\r\n20\u00a0units/kg 3 times weekly for 4 weeks, increased according to response\r\nat intervals of 4 weeks in steps of 20\u00a0units/kg 3 times weekly; total\r\nweekly dose may be divided into daily doses; maintenance dose, initially\r\nreduce dose by half then adjust according to response at intervals\r\nof 1\u20132 weeks; total weekly maintenance dose may be given as a single\r\ndose or in 3 or 7 divided doses; max. 720\u00a0units/kg weekly", "Name[NeoRecormon\u00ae (Roche) ] Injection, prefilled syringe, epoetin\r\nbeta, net price 500\u00a0units = \u00a33.75; 2000\u00a0units = \u00a314.98; 3000\u00a0units\r\n= \u00a322.47; 4000\u00a0units = \u00a329.96; 5000\u00a0units = \u00a337.47; 6000\u00a0units = \u00a344.94;\r\n10\u00a0000\u00a0units = \u00a370.14; 20\u00a0000\u00a0units = \u00a3140.28; 30\u00a0000\u00a0units = \u00a3224.69Excipients  include phenylalanine up to 300\u00a0micrograms/syringe (section\r\n9.4.1) Dose\u00a0symptomatic anaemia associated with chronic renal failure\r\n(see also MHRA/CHM advice), by subcutaneous injection, adult and child, initially 20\u00a0units/kg\r\n3 times weekly for 4 weeks, increased according to response at intervals\r\nof 4 weeks in steps of 20\u00a0units/kg 3 times weekly; total weekly dose\r\nmay be divided into daily doses; maintenance dose, initially reduce\r\ndose by half then adjust according to response at intervals of 1\u20132\r\nweeks; total weekly maintenance dose may be given as a single dose\r\nor in 3 or 7 divided doses; max. 720\u00a0units/kg weeklyBy intravenous injection over 2 minutes, adult and child, initially\r\n40\u00a0units/kg 3 times weekly for 4 weeks, increased according to response\r\nto 80\u00a0units/kg 3 times weekly after 4 weeks, with further increases\r\nif needed at intervals of 4 weeks in steps of 20\u00a0units/kg 3 times\r\nweekly; maintenance dose, initially reduce dose by half then adjust\r\naccording to response at intervals of 1\u20132 weeks; max. 720\u00a0units/kg\r\nweeklyNote\u00a0Subcutaneous route preferred in patients\r\nnot on haemodialysis. Reduce dose by approximately 25% if rise in\r\nhaemoglobin concentration exceeds 2\u00a0g/100\u00a0mL over 4 weeks or if haemoglobin\r\nconcentration approaches or exceeds 12\u00a0g/100\u00a0mL; if haemoglobin concentration\r\ncontinues to rise, despite dose reduction, suspend treatment until\r\nhaemoglobin concentration decreases and then restart at a dose approximately\r\n25% lower than the previous dosePrevention of anaemia of prematurity in neonates with\r\nbirth-weight of 0.75\u20131.5\u00a0kg and gestational age of less than 34 weeks, by subcutaneous injection, 250\u00a0units/kg 3 times weekly preferably\r\nstarting within 3 days of birth and continued for 6 weeksSymptomatic anaemia in adults with non-myeloid malignancies\r\nreceiving chemotherapy (see also MHRA/CHM advice), by subcutaneous injection, initially 450\u00a0units/kg weekly\r\n(as a single dose or in 3\u20137 divided doses), increased if necessary\r\nafter 4 weeks (if a rise in haemoglobin of at least 1\u00a0g/100\u00a0mL not\r\nachieved) to 900\u00a0units/kg weekly (as a single dose or in 3\u20137 divided\r\ndoses); if adequate response obtained reduce dose by 25\u201350%; max.\r\n60\u00a0000\u00a0units weeklyNote\u00a0Discontinue treatment if haemoglobin concentration\r\ndoes not increase by at least 1\u00a0g/100\u00a0mL after 8 weeks of therapy\r\n(response unlikely). Reduce dose by approximately 25\u201350% if rise in\r\nhaemoglobin concentration exceeds 2\u00a0g/100\u00a0mL over 4 weeks or if haemoglobin\r\nconcentration exceeds 12\u00a0g/100\u00a0mL; if haemoglobin concentration continues\r\nto rise, despite dose reduction, suspend treatment until haemoglobin\r\nconcentration decreases and then restart at a dose approximately 25%\r\nlower than the previous dose. Discontinue approximately 4 weeks after\r\nending chemotherapyTo increase yield of autologous blood (to avoid homologous\r\nblood) in predonation programme in moderate anaemia when blood-conserving\r\nprocedures are insufficient or unavailable, consult product literature\nMultidose injection, powder for\r\nreconstitution, epoetin beta, net price 50\u00a0000-unit vial = \u00a3374.48\r\n(with solvent)Excipients  include phenylalanine up to 5\u00a0mg/vial\r\n(section 9.4.1), benzyl alcohol (avoid in neonates, see Excipients ) Note\u00a0Avoid contact of reconstituted\r\ninjection with glass; use only plastic materialsDose\u00a0symptomatic anaemia associated with chronic renal failure\r\n(see also MHRA/CHM advice), by subcutaneous injection, adult and child over 3 years, initially\r\n20\u00a0units/kg 3 times weekly for 4 weeks, increased according to response\r\nat intervals of 4 weeks in steps of 20\u00a0units/kg 3 times weekly; total\r\nweekly dose may be divided into daily doses; maintenance dose, initially\r\nreduce dose by half then adjust according to response at intervals\r\nof 1\u20132 weeks; total weekly maintenance dose may be given as a single\r\ndose or in 3 or 7 divided doses; max. 720\u00a0units/kg weeklyBy intravenous injection over 2 minutes, adult and child over\r\n3 years, initially 40\u00a0units/kg 3 times weekly for 4 weeks, increased\r\naccording to response to 80\u00a0units/kg 3 times weekly after 4 weeks,\r\nwith further increases if needed at intervals of 4 weeks in steps\r\nof 20\u00a0units/kg 3 times weekly; maintenance dose, initially reduce\r\ndose by half then adjust according to response at intervals of 1\u20132\r\nweeks; max. 720\u00a0units/kg weeklyNote\u00a0Subcutaneous route preferred in patients\r\nnot on haemodialysis. Reduce dose by approximately 25% if rise in\r\nhaemoglobin concentration exceeds 2\u00a0g/100\u00a0mL over 4 weeks or if haemoglobin\r\nconcentration approaches or exceeds 12\u00a0g/100\u00a0mL; if haemoglobin concentration\r\ncontinues to rise, despite dose reduction, suspend treatment until\r\nhaemoglobin concentration decreases and then restart at a dose approximately\r\n25% lower than the previous doseSymptomatic anaemia in adults with non-myeloid malignancies\r\nreceiving chemotherapy (see also MHRA/CHM advice), by subcutaneous injection, initially 450\u00a0units/kg weekly\r\n(as a single dose or in 3\u20137 divided doses), increased if necessary\r\nafter 4 weeks (if a rise in haemoglobin of at least 1\u00a0g/100\u00a0mL not\r\nachieved) to 900\u00a0units/kg weekly (as a single dose or in 3\u20137 divided\r\ndoses); if adequate response obtained reduce dose by 25\u201350%; max.\r\n60\u00a0000\u00a0units weeklyNote\u00a0Discontinue treatment if haemoglobin concentration\r\ndoes not increase by at least 1\u00a0g/100\u00a0mL after 8 weeks of therapy\r\n(response unlikely). Reduce dose by approximately 25\u201350% if rise in\r\nhaemoglobin concentration exceeds 2\u00a0g/100\u00a0mL over 4 weeks or if haemoglobin\r\nconcentration exceeds 12\u00a0g/100\u00a0mL; if haemoglobin concentration continues\r\nto rise, despite dose reduction, suspend treatment until haemoglobin\r\nconcentration decreases and then restart at a dose approximately 25%\r\nlower than the previous dose. Discontinue approximately 4 weeks after\r\nending chemotherapyTo increase yield of autologous blood (to avoid homologous\r\nblood) in predonation programme in moderate anaemia when blood-conserving\r\nprocedures are insufficient or unavailable, consult product literature"], "pregnancy": "Pregnancy\u00a0no evidence of harm; benefits probably outweigh risk\r\nof anaemia and of transfusion in pregnancy"}]